Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SAN DIEGO, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), today provided a corporate update.
"Since the beginning of this year, we have continued to focus our efforts on creating long-term value through our lead product Vitaros® and our lead product candidate Femprox®," said Richard Pascoe, Chief Executive Officer of Apricus Bio. "The recent approval of Vitaros® in Europe marked a significant milestone for Apricus and for our commercial partners Takeda, Sandoz, and Bracco.
Help employers find you! Check out all the jobs and post your resume.
SAN DIEGO, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com), today provided a corporate update.
"Since the beginning of this year, we have continued to focus our efforts on creating long-term value through our lead product Vitaros® and our lead product candidate Femprox®," said Richard Pascoe, Chief Executive Officer of Apricus Bio. "The recent approval of Vitaros® in Europe marked a significant milestone for Apricus and for our commercial partners Takeda, Sandoz, and Bracco.
Help employers find you! Check out all the jobs and post your resume.
